Alvotech Posts $28.6M H1 Operating Income, Product Revenue Rises

Alvotech reported a H1 operating income of USD 28.639 million, swinging to a profit. The company's product revenue increased, and shares gained after hours. Alvotech also appointed Linda Jónsdóttir as Chief Financial Officer and acquired Ivers-Lee AG to expand packaging capacity. The company partnered with Advanz Pharma to launch a Cimzia biosimilar in Europe.

Alvotech (NASDAQ: ALVO) reported robust financial results for the first half of 2025, demonstrating significant growth and strategic advancements in the biosimilar market. The company's operating income surged to USD 28.639 million, marking a substantial turnaround from the previous period's loss. Product revenue increased by 210% year-over-year to USD 204.7 million, driven by strong sales of AVT02 (Humira biosimilar) and AVT04 (Stelara biosimilar) in various markets [1].

The company's liquidity position has been bolstered by a strong cash position of USD 151.5 million, achieved through robust operational performance and successful fundraising efforts. Alvotech completed two SDR offerings, raising approximately SEK 789 million, and amended its term loan to reduce interest expenses by USD 8.2 million annually [1].

Strategic acquisitions and partnerships have been key drivers of Alvotech's growth. The company acquired Xbrane's R&D facilities in Sweden and Ivers-Lee Group in Switzerland, strengthening its end-to-end biosimilar platform. Additionally, Alvotech expanded commercial partnerships with Advanz Pharma and Dr. Reddy's Laboratories, covering multiple biosimilar candidates [1].

Linda Jónsdóttir was appointed as the new Chief Financial Officer, replacing Joel Morales, who continues to serve in an advisory role. Jónsdóttir brings extensive experience in finance and corporate leadership, having held senior positions at Marel for over 15 years [1].

References:
[1] https://www.stocktitan.net/news/ALVO/alvotech-reports-results-for-the-first-six-months-of-2025-and-4az2rb2vi2b5.html